Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus

X
Trial Profile

DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DOS
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 22 Feb 2023 Results published in the Mannkind media release.
    • 22 Feb 2023 According to Mannkind media release, the oral presentation describing meal challenge results will be presented at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin from February 22nd-25th.
    • 10 Nov 2022 According to MannKind Corporation Media Release, data showing effects of the three treatment groups on glycemic control are being readied for publication and are planned to be presented at a diabetes conference in 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top